Incyte Quarterly Cash Flow Statement
NASDAQ: INCYHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Incyte free cash flow
In the quarter ended Mar 31, 2026, Incyte generated $369.4 million of operating cash flow. That left free cash flow of $369.4 million, a free-cash-flow margin of 29.0% of revenue. Free cash flow was up 38.8% from the prior year's $266.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Incyte cash flow statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 303.33M | 299.28M | 424.17M | 405.00M | 158.20M | 201.21M | 106.46M | -444.60M | 169.55M | 201.08M | 171.27M | 203.55M |
| Net Income growth (YoY) | +91.73% | +48.74% | +298.45% | — | -6.69% | +0.07% | -37.84% | -318.43% | +681.22% | +606.51% | +51.87% | +26.09% |
| Depreciation & Amortization | 23.80M | 23.98M | 24.02M | 22.92M | 22.36M | 22.73M | 22.52M | 22.05M | 21.95M | 21.76M | 21.39M | 20.30M |
| Stock-Based Compensation | 64.13M | 62.16M | 61.60M | 64.61M | 60.98M | 71.72M | 77.92M | 56.64M | 59.78M | 59.99M | 48.00M | 54.52M |
| Change in Working Capital | -91.34M | 103.20M | -60.42M | -582.96M | 13.02M | 83.59M | 108.87M | -153.45M | 99.24M | -73.25M | -91.12M | 102.32M |
| Operating Cash Flow | 369.35M | 543.30M | 559.39M | 44.74M | 266.07M | 381.22M | 310.87M | -575.56M | 218.81M | 147.73M | 147.84M | 306.53M |
| Investing Cash Flow | -88.20M | -37.42M | -47.42M | -18.87M | 1.10M | -21.46M | 38.27M | 213.82M | -73.11M | -154.50M | -17.19M | -7.43M |
| Share Repurchases | — | 0 | 0 | — | — | 0 | -103.00K | — | — | 0 | 0 | — |
| Financing Cash Flow | 84.82M | 137.74M | -12.78M | -11.25M | -12.68M | 20.39M | -32.35M | -2.00B | -12.41M | 346.00K | -37.26M | 12.87M |
| Net Change in Cash | 363.28M | 642.82M | 500.04M | 13.43M | 253.94M | 383.61M | 316.92M | -2.36B | 132.61M | -13.73M | 96.11M | 310.07M |
| Free Cash Flow | 369.35M | 543.30M | 559.39M | 44.74M | 266.07M | 381.22M | 310.87M | -575.56M | 218.81M | 147.73M | 147.84M | 306.53M |
This table shows 12 quarterly periods of Incyte's cash flow statement, from Q1 2026 back to Q2 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INCY's reporting calendar. What is a cash flow statement?